Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma.

Castillo L, Young AIJ, Mawson A, Schafranek P, Steinmann AM, Nessem D, Parkin A, Johns A, Chou A, Law AMK, Lucas MC, Murphy KJ, Deng N, Gallego-Ortega D, Caldon CE; Australian Pancreatic Cancer Genome Initiative (APGI), Timpson P, Pajic M, Ormandy CJ, Oakes SR.

Oncogene. 2019 Nov 18. doi: 10.1038/s41388-019-1091-0. [Epub ahead of print]

PMID:
31735913
2.

CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.

Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, Cox TR, Timpson P.

Trends Cancer. 2019 Nov;5(11):724-741. doi: 10.1016/j.trecan.2019.09.010. Epub 2019 Oct 21. Review.

PMID:
31735290
3.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.

4.

Morphogenesis of extra-embryonic tissues directs the remodelling of the mouse embryo at implantation.

Christodoulou N, Weberling A, Strathdee D, Anderson KI, Timpson P, Zernicka-Goetz M.

Nat Commun. 2019 Aug 7;10(1):3557. doi: 10.1038/s41467-019-11482-5.

5.

Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.

Parkin A, Man J, Timpson P, Pajic M.

FEBS J. 2019 Sep;286(18):3510-3539. doi: 10.1111/febs.15011. Epub 2019 Aug 5. Review.

6.

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR.

Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.

7.

ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling.

Pinho AV, Van Bulck M, Chantrill L, Arshi M, Sklyarova T, Herrmann D, Vennin C, Gallego-Ortega D, Mawson A, Giry-Laterriere M, Magenau A, Leuckx G, Baeyens L, Gill AJ, Phillips P, Timpson P, Biankin AV, Wu J, Rooman I.

Nat Commun. 2018 Nov 30;9(1):5083. doi: 10.1038/s41467-018-07497-z.

8.

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma.

Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M.

Diseases. 2018 Nov 13;6(4). pii: E103. doi: 10.3390/diseases6040103. Review.

9.

Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.

Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P.

Gut. 2019 Apr;68(4):742-758. doi: 10.1136/gutjnl-2018-316822. Epub 2018 Nov 5. Review.

10.

Recent advances in understanding the complexities of metastasis.

Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P.

Version 2. F1000Res. 2018 Aug 1 [revised 2018 Jan 1];7. pii: F1000 Faculty Rev-1169. doi: 10.12688/f1000research.15064.2. eCollection 2018. Review.

11.

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara D, Mittal D, Saunus JM, Lakhani SR, López JA, Spring KJ, Timpson P, Gabrielli B, Waddell N, Khanna KK.

EMBO Mol Med. 2018 Sep;10(9). pii: e8566. doi: 10.15252/emmm.201708566.

12.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A.

Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.

13.

Removing physiological motion from intravital and clinical functional imaging data.

Warren SC, Nobis M, Magenau A, Mohammed YH, Herrmann D, Moran I, Vennin C, Conway JR, Mélénec P, Cox TR, Wang Y, Morton JP, Welch HC, Strathdee D, Anderson KI, Phan TG, Roberts MS, Timpson P.

Elife. 2018 Jul 9;7. pii: e35800. doi: 10.7554/eLife.35800.

14.

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.

Cell Rep. 2018 Jun 12;23(11):3312-3326. doi: 10.1016/j.celrep.2018.05.038.

15.

MASTL overexpression promotes chromosome instability and metastasis in breast cancer.

Rogers S, McCloy RA, Parker BL, Gallego-Ortega D, Law AMK, Chin VT, Conway JRW, Fey D, Millar EKA, O'Toole S, Deng N, Swarbrick A, Chastain PD, Cesare AJ, Timpson P, Caldon CE, Croucher DR, James DE, Watkins DN, Burgess A.

Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.

16.

Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism.

Lancaster GI, Langley KG, Berglund NA, Kammoun HL, Reibe S, Estevez E, Weir J, Mellett NA, Pernes G, Conway JRW, Lee MKS, Timpson P, Murphy AJ, Masters SL, Gerondakis S, Bartonicek N, Kaczorowski DC, Dinger ME, Meikle PJ, Bond PJ, Febbraio MA.

Cell Metab. 2018 May 1;27(5):1096-1110.e5. doi: 10.1016/j.cmet.2018.03.014. Epub 2018 Apr 19.

17.

Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth.

Rath N, Munro J, Cutiongco MF, Jagiełło A, Gadegaard N, McGarry L, Unbekandt M, Michalopoulou E, Kamphorst JJ, Sumpton D, Mackay G, Vennin C, Pajic M, Timpson P, Olson MF.

Cancer Res. 2018 Jun 15;78(12):3321-3336. doi: 10.1158/0008-5472.CAN-17-1339. Epub 2018 Apr 18.

18.

Molecular mobility and activity in an intravital imaging setting - implications for cancer progression and targeting.

Nobis M, Warren SC, Lucas MC, Murphy KJ, Herrmann D, Timpson P.

J Cell Sci. 2018 Mar 6;131(5). pii: jcs206995. doi: 10.1242/jcs.206995. Review.

19.

Shedding new light on RhoA signalling as a drug target in vivo using a novel RhoA-FRET biosensor mouse.

Nobis M, Herrmann D, Warren SC, Strathdee D, Cox TR, Anderson KI, Timpson P.

Small GTPases. 2018 Mar 21:1-8. doi: 10.1080/21541248.2018.1438024. [Epub ahead of print]

PMID:
29457531
20.

Acute compressive stress activates RHO/ROCK-mediated cellular processes.

Boyle ST, Kular J, Nobis M, Ruszkiewicz A, Timpson P, Samuel MS.

Small GTPases. 2018 Feb 17:1-17. doi: 10.1080/21541248.2017.1413496. [Epub ahead of print]

PMID:
29455593
21.

∆133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling.

Campbell H, Fleming N, Roth I, Mehta S, Wiles A, Williams G, Vennin C, Arsic N, Parkin A, Pajic M, Munro F, McNoe L, Black M, McCall J, Slatter TL, Timpson P, Reddel R, Roux P, Print C, Baird MA, Braithwaite AW.

Nat Commun. 2018 Jan 17;9(1):254. doi: 10.1038/s41467-017-02408-0.

22.

Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.

Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P.

Gastroenterology. 2018 Mar;154(4):820-838. doi: 10.1053/j.gastro.2017.11.280. Epub 2017 Dec 26. Review.

PMID:
29287624
23.

Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.

Conway JRW, Vennin C, Cazet AS, Herrmann D, Murphy KJ, Warren SC, Wullkopf L, Boulghourjian A, Zaratzian A, Da Silva AM, Pajic M, Morton JP, Cox TR, Timpson P.

Sci Rep. 2017 Dec 4;7(1):16887. doi: 10.1038/s41598-017-17177-5.

24.

Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion.

Young AI, Timpson P, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Cell Adh Migr. 2018;12(6):513-523. doi: 10.1080/19336918.2017.1393591. Epub 2017 Dec 21. Review.

25.

Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy.

Vennin C, Cox TR, Pajic M, Timpson P.

Oncotarget. 2017 Oct 3;8(49):84635-84636. doi: 10.18632/oncotarget.21468. eCollection 2017 Oct 17. No abstract available.

26.

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.

Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ; Australian Pancreatic Cancer Genome Initiative (APGI), Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M.

Gut. 2018 Dec;67(12):2142-2155. doi: 10.1136/gutjnl-2017-315144. Epub 2017 Oct 28.

27.

Effective modulation of stromal signaling through ROCK inhibition: Is it all in the timing?

Chin VT, Vennin C, Timpson P, Pajic M.

Mol Cell Oncol. 2017 May 26;4(5):e1333973. doi: 10.1080/23723556.2017.1333973. eCollection 2017.

28.

'MCC' protein interacts with E-cadherin and β-catenin strengthening cell-cell adhesion of HCT116 colon cancer cells.

Benthani FA, Herrmann D, Tran PN, Pangon L, Lucas MC, Allam AH, Currey N, Al-Sohaily S, Giry-Laterriere M, Warusavitarne J, Timpson P, Kohonen-Corish MRJ.

Oncogene. 2018 Feb 1;37(5):663-672. doi: 10.1038/onc.2017.362. Epub 2017 Oct 16.

PMID:
29035389
29.

A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts.

Nobis M, Herrmann D, Warren SC, Kadir S, Leung W, Killen M, Magenau A, Stevenson D, Lucas MC, Reischmann N, Vennin C, Conway JRW, Boulghourjian A, Zaratzian A, Law AM, Gallego-Ortega D, Ormandy CJ, Walters SN, Grey ST, Bailey J, Chtanova T, Quinn JMW, Baldock PA, Croucher PI, Schwarz JP, Mrowinska A, Zhang L, Herzog H, Masedunskas A, Hardeman EC, Gunning PW, Del Monte-Nieto G, Harvey RP, Samuel MS, Pajic M, McGhee EJ, Johnsson AE, Sansom OJ, Welch HCE, Morton JP, Strathdee D, Anderson KI, Timpson P.

Cell Rep. 2017 Oct 3;21(1):274-288. doi: 10.1016/j.celrep.2017.09.022.

30.

Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.

Vennin C, Rath N, Pajic M, Olson MF, Timpson P.

Small GTPases. 2017 Oct 3:1-8. doi: 10.1080/21541248.2017.1345712. [Epub ahead of print]

PMID:
28972449
31.

Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression.

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R.

Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160.

32.

Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors.

Conway JRW, Warren SC, Timpson P.

Methods. 2017 Sep 1;128:78-94. doi: 10.1016/j.ymeth.2017.04.014. Epub 2017 Apr 19. Review.

PMID:
28435000
33.

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, Melenec P, Walters SN, Del Monte-Nieto G, Conway JR, Nobis M, Allam AH, McCloy RA, Currey N, Pinese M, Boulghourjian A, Zaratzian A, Adam AA, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NL, Phan T, Jain R, Weninger W, McGhee EJ, Whan R, Johns AL, Samra JS, Chantrill L, Gill AJ, Kohonen-Corish M, Harvey RP, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI), Evans TR, Anderson KI, Grey ST, Ormandy CJ, Gallego-Ortega D, Wang Y, Samuel MS, Sansom OJ, Burgess A, Cox TR, Morton JP, Pajic M, Timpson P.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8504. doi: 10.1126/scitranslmed.aai8504.

34.

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.

Harris NLE, Vennin C, Conway JRW, Vine KL, Pinese M, Cowley MJ, Shearer RF, Lucas MC, Herrmann D, Allam AH, Pajic M, Morton JP; Australian Pancreatic Cancer Genome Initiative, Biankin AV, Ranson M, Timpson P, Saunders DN.

Oncogene. 2017 Jul 27;36(30):4288-4298. doi: 10.1038/onc.2017.63. Epub 2017 Mar 27.

35.

Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.

Chang J, Lucas MC, Leonte LE, Garcia-Montolio M, Singh LB, Findlay AD, Deodhar M, Foot JS, Jarolimek W, Timpson P, Erler JT, Cox TR.

Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257.

36.

Annexin A6-A multifunctional scaffold in cell motility.

Grewal T, Hoque M, Conway JRW, Reverter M, Wahba M, Beevi SS, Timpson P, Enrich C, Rentero C.

Cell Adh Migr. 2017 May 4;11(3):288-304. doi: 10.1080/19336918.2016.1268318. Epub 2017 Jan 6. Review.

37.

Recruitment Kinetics of Tropomyosin Tpm3.1 to Actin Filament Bundles in the Cytoskeleton Is Independent of Actin Filament Kinetics.

Appaduray MA, Masedunskas A, Bryce NS, Lucas CA, Warren SC, Timpson P, Stear JH, Gunning PW, Hardeman EC.

PLoS One. 2016 Dec 15;11(12):e0168203. doi: 10.1371/journal.pone.0168203. eCollection 2016.

38.

MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.

Young AI, Law AM, Castillo L, Chong S, Cullen HD, Koehler M, Herzog S, Brummer T, Lee EF, Fairlie WD, Lucas MC, Herrmann D, Allam A, Timpson P, Watkins DN, Millar EK, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Breast Cancer Res. 2016 Dec 8;18(1):125.

39.

Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression.

Vennin C, Herrmann D, Lucas MC, Timpson P.

F1000Res. 2016 May 16;5. pii: F1000 Faculty Rev-892. doi: 10.12688/f1000research.8090.1. eCollection 2016. Review.

40.

The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Roth I, Campbell H, Rubio C, Vennin C, Wilson M, Wiles A, Williams G, Woolley A, Timpson P, Berridge MV, Fleming N, Baird M, Braithwaite AW.

Oncogene. 2016 Sep 22;35(38):4981-9. doi: 10.1038/onc.2016.45. Epub 2016 Mar 21.

PMID:
26996665
41.

Differential Rac1 signalling by guanine nucleotide exchange factors implicates FLII in regulating Rac1-driven cell migration.

Marei H, Carpy A, Woroniuk A, Vennin C, White G, Timpson P, Macek B, Malliri A.

Nat Commun. 2016 Feb 18;7:10664. doi: 10.1038/ncomms10664.

42.

Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue.

Erami Z, Herrmann D, Warren SC, Nobis M, McGhee EJ, Lucas MC, Leung W, Reischmann N, Mrowinska A, Schwarz JP, Kadir S, Conway JRW, Vennin C, Karim SA, Campbell AD, Gallego-Ortega D, Magenau A, Murphy KJ, Ridgway RA, Law AM, Walters SN, Grey ST, Croucher DR, Zhang L, Herzog H, Hardeman EC, Gunning PW, Ormandy CJ, Evans TRJ, Strathdee D, Sansom OJ, Morton JP, Anderson KI, Timpson P.

Cell Rep. 2016 Jan 5;14(1):152-167. doi: 10.1016/j.celrep.2015.12.020. Epub 2015 Dec 24.

43.

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.

Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Herrmann D, Salomon R, Young AI, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JR, Rabinovich B, Millar EK, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole S, Green AR, Timpson P, Gee JM, Ellis IO, Clark SJ, Ormandy CJ.

PLoS Biol. 2015 Dec 30;13(12):e1002330. doi: 10.1371/journal.pbio.1002330. eCollection 2015 Dec.

44.

A Negative Regulatory Mechanism Involving 14-3-3ζ Limits Signaling Downstream of ROCK to Regulate Tissue Stiffness in Epidermal Homeostasis.

Kular J, Scheer KG, Pyne NT, Allam AH, Pollard AN, Magenau A, Wright RL, Kolesnikoff N, Moretti PA, Wullkopf L, Stomski FC, Cowin AJ, Woodcock JM, Grimbaldeston MA, Pitson SM, Timpson P, Ramshaw HS, Lopez AF, Samuel MS.

Dev Cell. 2015 Dec 21;35(6):759-74. doi: 10.1016/j.devcel.2015.11.026.

45.

Annexin A6 and Late Endosomal Cholesterol Modulate Integrin Recycling and Cell Migration.

García-Melero A, Reverter M, Hoque M, Meneses-Salas E, Koese M, Conway JR, Johnsen CH, Alvarez-Guaita A, Morales-Paytuvi F, Elmaghrabi YA, Pol A, Tebar F, Murray RZ, Timpson P, Enrich C, Grewal T, Rentero C.

J Biol Chem. 2016 Jan 15;291(3):1320-35. doi: 10.1074/jbc.M115.683557. Epub 2015 Nov 17.

46.

Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.

Vlahov N, Scrace S, Soto MS, Grawenda AM, Bradley L, Pankova D, Papaspyropoulos A, Yee KS, Buffa F, Goding CR, Timpson P, Sibson N, O'Neill E.

Curr Biol. 2015 Dec 7;25(23):3019-34. doi: 10.1016/j.cub.2015.09.072. Epub 2015 Nov 5.

47.

Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities.

Chin VT, Nagrial AM, Chou A, Biankin AV, Gill AJ, Timpson P, Pajic M.

Expert Rev Mol Med. 2015 Oct 28;17:e17. doi: 10.1017/erm.2015.17. Review.

48.

There are four dynamically and functionally distinct populations of E-cadherin in cell junctions.

Erami Z, Timpson P, Yao W, Zaidel-Bar R, Anderson KI.

Biol Open. 2015 Oct 15;4(11):1481-9. doi: 10.1242/bio.014159.

49.

The cross-talk of LDL-cholesterol with cell motility: insights from the Niemann Pick Type C1 mutation and altered integrin trafficking.

Hoque M, Rentero C, Conway JR, Murray RZ, Timpson P, Enrich C, Grewal T.

Cell Adh Migr. 2015;9(5):384-91. doi: 10.1080/19336918.2015.1019996. Epub 2015 Sep 14.

50.

The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.

Ooms LM, Binge LC, Davies EM, Rahman P, Conway JR, Gurung R, Ferguson DT, Papa A, Fedele CG, Vieusseux JL, Chai RC, Koentgen F, Price JT, Tiganis T, Timpson P, McLean CA, Mitchell CA.

Cancer Cell. 2015 Aug 10;28(2):155-69. doi: 10.1016/j.ccell.2015.07.003.

Supplemental Content

Loading ...
Support Center